Find Clinical Drug Pipeline Developments & Deals for Sinapultide


All Data

Filters Filter refresh
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sinapultide

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co

            Deal Size: $20.2 million Upfront Cash: Undisclosed

            Deal Type: Public Offering May 22, 2020


            Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinical development of AEROSURF;pre-clinical studies of SERCA2a activators.